Concepedia

Publication | Open Access

Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104

DOIFull Paper Access

243

Citations

42

References

2007

Year

Adam V. Patterson, Dianne M. Ferry, Shelley J. Edmunds, Yongchuan Gu, Rachelle S. Singleton, Kashyap Patel, Susan M. Pullen, Kevin O. Hicks, Sophie P. Syddall, Graham J. Atwell,
Clinical Cancer Research

Abstract

PR-104 is a novel hypoxia-activated DNA cross-linking agent with marked activity against human tumor xenografts, both as monotherapy and combined with radiotherapy and chemotherapy.

References

YearCitations

Page 1